Preoperative embolization of cerebral arteriovenous malformations with onyx

E. F. Hauck, B. G. Welch, J. A. White, P. D. Purdy, L. G. Pride, D. Samson

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Preoperative embolization facilitates the surgical management of complex cerebral arteriovenous malformations (cAVMs). This analysis aims to investigate the risks for preoperative cAVM embolization with Onyx. MATERIALS AND METHODS: We retrospectively analyzed clinical data of all patients who underwent embolization with Onyx as a preoperative treatment of cAVMs at our institution since 2005 (US Food and Drug Administration [FDA] approval). Patients with arteriovenous fistulas were excluded. A total of 107 patients were treated for cAVMs during the study period. Of those patients, 41 underwent cAVM embolizations with Onyx in 82 procedures. RESULTS: After the embolization, the cAVM diameter was reduced from 3.71 ± 1.55 cm to 3.06 ± 1.89 cm (P < .05). Median volume reduction was 75%. Complete occlusion with embolization alone was achieved in 4 (10%) cAVMs. The recurrence rate for completely occluded cAVMs was 50% (2 patients). A total of 71 % of the 41 patients treated with Onyx underwent surgery, and 15% underwent radiosurgery. There were 9% who have not yet received definitive treatment of their residual cAVMs. A new permanent neurologic deficit occurred in 5 patients (6.1 % per procedure or 12.2% per patient). CONCLUSIONS: A considerable risk for a permanent neurologic deficit remains for cAVM embolization with Onyx. The risk has to be carefully weighted against the benefit of volume reduction in the treatment of cAVMs.

Original languageEnglish (US)
Pages (from-to)492-495
Number of pages4
JournalAmerican Journal of Neuroradiology
Volume30
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Intracranial Arteriovenous Malformations
Neurologic Manifestations
Drug Approval
Radiosurgery
Arteriovenous Fistula
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging

Cite this

Preoperative embolization of cerebral arteriovenous malformations with onyx. / Hauck, E. F.; Welch, B. G.; White, J. A.; Purdy, P. D.; Pride, L. G.; Samson, D.

In: American Journal of Neuroradiology, Vol. 30, No. 3, 03.2009, p. 492-495.

Research output: Contribution to journalArticle

@article{25a601f469984a00903b673a4cf321d0,
title = "Preoperative embolization of cerebral arteriovenous malformations with onyx",
abstract = "Preoperative embolization facilitates the surgical management of complex cerebral arteriovenous malformations (cAVMs). This analysis aims to investigate the risks for preoperative cAVM embolization with Onyx. MATERIALS AND METHODS: We retrospectively analyzed clinical data of all patients who underwent embolization with Onyx as a preoperative treatment of cAVMs at our institution since 2005 (US Food and Drug Administration [FDA] approval). Patients with arteriovenous fistulas were excluded. A total of 107 patients were treated for cAVMs during the study period. Of those patients, 41 underwent cAVM embolizations with Onyx in 82 procedures. RESULTS: After the embolization, the cAVM diameter was reduced from 3.71 ± 1.55 cm to 3.06 ± 1.89 cm (P < .05). Median volume reduction was 75{\%}. Complete occlusion with embolization alone was achieved in 4 (10{\%}) cAVMs. The recurrence rate for completely occluded cAVMs was 50{\%} (2 patients). A total of 71 {\%} of the 41 patients treated with Onyx underwent surgery, and 15{\%} underwent radiosurgery. There were 9{\%} who have not yet received definitive treatment of their residual cAVMs. A new permanent neurologic deficit occurred in 5 patients (6.1 {\%} per procedure or 12.2{\%} per patient). CONCLUSIONS: A considerable risk for a permanent neurologic deficit remains for cAVM embolization with Onyx. The risk has to be carefully weighted against the benefit of volume reduction in the treatment of cAVMs.",
author = "Hauck, {E. F.} and Welch, {B. G.} and White, {J. A.} and Purdy, {P. D.} and Pride, {L. G.} and D. Samson",
year = "2009",
month = "3",
doi = "10.3174/ajnr.A1376",
language = "English (US)",
volume = "30",
pages = "492--495",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "3",

}

TY - JOUR

T1 - Preoperative embolization of cerebral arteriovenous malformations with onyx

AU - Hauck, E. F.

AU - Welch, B. G.

AU - White, J. A.

AU - Purdy, P. D.

AU - Pride, L. G.

AU - Samson, D.

PY - 2009/3

Y1 - 2009/3

N2 - Preoperative embolization facilitates the surgical management of complex cerebral arteriovenous malformations (cAVMs). This analysis aims to investigate the risks for preoperative cAVM embolization with Onyx. MATERIALS AND METHODS: We retrospectively analyzed clinical data of all patients who underwent embolization with Onyx as a preoperative treatment of cAVMs at our institution since 2005 (US Food and Drug Administration [FDA] approval). Patients with arteriovenous fistulas were excluded. A total of 107 patients were treated for cAVMs during the study period. Of those patients, 41 underwent cAVM embolizations with Onyx in 82 procedures. RESULTS: After the embolization, the cAVM diameter was reduced from 3.71 ± 1.55 cm to 3.06 ± 1.89 cm (P < .05). Median volume reduction was 75%. Complete occlusion with embolization alone was achieved in 4 (10%) cAVMs. The recurrence rate for completely occluded cAVMs was 50% (2 patients). A total of 71 % of the 41 patients treated with Onyx underwent surgery, and 15% underwent radiosurgery. There were 9% who have not yet received definitive treatment of their residual cAVMs. A new permanent neurologic deficit occurred in 5 patients (6.1 % per procedure or 12.2% per patient). CONCLUSIONS: A considerable risk for a permanent neurologic deficit remains for cAVM embolization with Onyx. The risk has to be carefully weighted against the benefit of volume reduction in the treatment of cAVMs.

AB - Preoperative embolization facilitates the surgical management of complex cerebral arteriovenous malformations (cAVMs). This analysis aims to investigate the risks for preoperative cAVM embolization with Onyx. MATERIALS AND METHODS: We retrospectively analyzed clinical data of all patients who underwent embolization with Onyx as a preoperative treatment of cAVMs at our institution since 2005 (US Food and Drug Administration [FDA] approval). Patients with arteriovenous fistulas were excluded. A total of 107 patients were treated for cAVMs during the study period. Of those patients, 41 underwent cAVM embolizations with Onyx in 82 procedures. RESULTS: After the embolization, the cAVM diameter was reduced from 3.71 ± 1.55 cm to 3.06 ± 1.89 cm (P < .05). Median volume reduction was 75%. Complete occlusion with embolization alone was achieved in 4 (10%) cAVMs. The recurrence rate for completely occluded cAVMs was 50% (2 patients). A total of 71 % of the 41 patients treated with Onyx underwent surgery, and 15% underwent radiosurgery. There were 9% who have not yet received definitive treatment of their residual cAVMs. A new permanent neurologic deficit occurred in 5 patients (6.1 % per procedure or 12.2% per patient). CONCLUSIONS: A considerable risk for a permanent neurologic deficit remains for cAVM embolization with Onyx. The risk has to be carefully weighted against the benefit of volume reduction in the treatment of cAVMs.

UR - http://www.scopus.com/inward/record.url?scp=64549100339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549100339&partnerID=8YFLogxK

U2 - 10.3174/ajnr.A1376

DO - 10.3174/ajnr.A1376

M3 - Article

C2 - 19112062

AN - SCOPUS:64549100339

VL - 30

SP - 492

EP - 495

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 3

ER -